What is the Current Role for Vitamin D and the Risk of Stroke?

Author(s): Antonio Siniscalchi*, Piergiorgio Lochner, Sabrina Anticoli, Domenico Chirchiglia, Giovambattista De Sarro, Luca Gallelli.

Journal Name: Current Neurovascular Research

Volume 16 , Issue 2 , 2019

Become EABM
Become Reviewer

Abstract:

Introduction: Increasing evidence supports the relationship between vitamin D and stroke. Vitamin D has now been proposed as a prognostic biomarker also for functional outcome in stroke patients.

Methods: A revision of the data suggests that low vitamin D is associated more with ischemic than with haemorrhagic stroke, even if the role of optimal vitamin D levels for vascular wall is still unclear. Vitamin D deficiency induces with different mechanisms an alteration of vascular wall.

Results: However, to date, the research supporting the effectiveness of vitamin D supplementation in stroke and in post-stroke recovery is still inadequate and conclusive evidences have not been published.

Conclusion: In this review, we provide a better understanding of the role of vitamin D in stroke.

Keywords: Stroke, vitamin D, biomarker, supplementation vitamin D, cholecalciferol, neurological diseases.

[1]
Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-81.
[2]
Mytton J, Frater AP, Oakley G, Murphy E, Barber MJ, Jahfar S. Vitamin D deficiency in multicultural primary care: A case series of 299 patients. Br J Gen Pract 2007; 57(540): 577-9.
[3]
Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008; 87(4): 1087S-91S.
[4]
Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011; 364(3): 248-54.
[5]
Feart C, Helmer C, Merle B, et al. Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer’s disease in older adults. Alzheimers Dement 2017; 13(11): 1207-16.
[6]
Landel V, Annweiler C, Millet P, Morello M, Feron F. Vitamin D, cognition and alzheimer’s disease: The therapeutic benefit is in the D-Tails. J Alzheimers Dis 2016; 53(2): 419-44.
[7]
Lucas RM, Byrne SN, Correale J, Ilschner S, Hart PH. Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegener Dis Manag 2015; 5(5): 413-24.
[8]
Miclea A, Miclea M, Pistor M, Hoepner A, Chan A, Hoepner R. Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity. Brain Behav 2017; 7(8)e00761
[9]
Barnard K, Colon-Emeric C. Extraskeletal effects of vitamin D in older adults: Cardiovascular disease, mortality, mood, and cognition. Am J Geriatr Pharmacother 2010; 8(1): 4-33.
[10]
Wang A, Liu J, Meng X, et al. Association between oxidized low-density lipoprotein and cognitive impairment in patients with ischemic stroke. Eur J Neurol 2018; 25(1): 185-91.
[11]
Sun Q, Pan A, Hu FB, Manson JE, Rexrode KM. 25-Hydroxyvitamin D levels and the risk of stroke: A prospective study and meta-analysis. Stroke 2012; 43(6): 1470-7.
[12]
Daubail B, Jacquin A, Guilland JC, et al. Serum 25-hydroxyvitamin D predicts severity and prognosis in stroke patients. Eur J Neurol 2013; 20(1): 57-61.
[13]
Judd SE, Morgan CJ, Panwar B, et al. Vitamin D deficiency and incident stroke risk in community-living black and white adults. Int J Stroke 2016; 11(1): 93-102.
[14]
Zhang X, Tu W, Manson JE, et al. Racial/ethnic differences in 25-hydroxy vitamin D and parathyroid hormone levels and cardiovascular disease risk among postmenopausal women. J Am Heart Assoc 2019; 8(4)e011021
[15]
Qiu H, Wang M, Mi D, Zhao J, Tu W, Liu Q. Vitamin D status and the risk of recurrent stroke and mortality in ischemic stroke patients: Data from a 24-month follow-up study in China. J Nutr Health Aging 2017; 21(7): 766-71.
[16]
Daubail B, Jacquin A, Guilland JC, et al. Association between serum concentration of vitamin D and 1-year mortality in stroke patients. Cerebrovasc Dis 2014; 37(5): 364-7.
[17]
Kim K, Cho KH, Im SH, Choi J, Yu J, Kim M. Decrement of serum vitamin D level after stroke. Ann Rehabil Med 2017; 41(6): 944-50.
[18]
Moretti R, Morelli ME, Caruso P. Vitamin D in neurological diseases: A rationale for a pathogenic impact. Int J Mol Sci 2018; 19: 18.
[19]
Wang Y, Ji H, Tong Y, Zhang ZB. Prognostic value of serum 25-hydroxyvitamin D in patients with stroke. Neurochem Res 2014; 39(7): 1332-7.
[20]
Tu WJ, Zhao SJ, Xu DJ, Chen H. Serum 25-hydroxyvitamin D predicts the short-term outcomes of Chinese patients with acute ischaemic stroke. Clin Sci (Lond) 2014; 126(5): 339-46.
[21]
Turetsky A, Goddeau RP Jr, Henninger N. Low serum vitamin D is independently associated with larger lesion volumes after ischemic stroke. J Stroke Cerebrovasc Dis 2015; 24(7): 1555-63.
[22]
Huang H, Zheng T, Wang S, Wei L, Wang Q, Sun Z. Serum 25-hydroxyvitamin D predicts early recurrent stroke in ischemic stroke patients. Nutr Metab Cardiovasc Dis 2016; 26(10): 908-14.
[23]
Park KY, Chung PW, Kim YB, et al. Serum vitamin D status as a predictor of prognosis in patients with acute ischemic stroke. Cerebrovasc Dis 2015; 40(1-2): 73-80.
[24]
Gu Y, Luan X, Ren W, Zhu L, He J. Impact of seasons on stroke-related depression, mediated by vitamin D status. BMC Psychiatry 2018; 18(1): 359.
[25]
Hu W, Liu D, Li Q, Wang L, Tang Q, Wang G. Decreasing serum 25-hydroxyvitamin D levels and risk of early neurological deterioration in patients with ischemic stroke. Brain Behav 2019; 9(3)e01227
[26]
Lelli D, Perez-Bazan LM, Calle Egusquiza A, et al. 25(OH) vitamin D and functional outcomes in older adults admitted to rehabilitation units. The safari study. Osteoporos Int 2019; 4: 887-95.
[27]
Sato Y, Kuno H, Asoh T, Honda Y, Oizumi K. Expression of concern: Effect of immobilization on vitamin D status and bone mass in chronically hospitalized disabled stroke patients. Age Ageing 2019; 28(3): 265-9.
[28]
Chen H, Liu Y, Huang G, Zhu J, Feng W, He J. Association between vitamin D status and cognitive impairment in acute ischemic stroke patients: A prospective cohort study. Clin Interv Aging 2018; 13: 2503-9.
[29]
Siniscalchi A, Gallelli L, Malferrari G, et al. Cerebral stroke injury: The role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol 2014; 25(2): 131-7.
[30]
Siniscalchi A, Iannacchero R, Anticoli S, Pezzella FR, De Sarro G, Gallelli L. Anti-inflammatory Strategies in Stroke: A Potential Therapeutic Target. Curr Vasc Pharmacol 2016; 14(1): 98-105.
[31]
Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13(3): 100-5.
[32]
Brouwer-Brolsma EM, de Groot LC. Vitamin D and cognition in older adults: An update of recent findings. Curr Opin Clin Nutr Metab Care 2015; 18(1): 11-6.
[33]
Muscogiuri G, Annweiler C, Duval G, et al. Vitamin D and cardiovascular disease: From atherosclerosis to myocardial infarction and stroke. Int J Cardiol 2017; 230: 577-84.
[34]
Hamdy Al-Said N, Abd El Ghaffar Mohamed N, Salam RF, Fawzy MW. Vitamin D as a risk factor for premature atherosclerosis in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2015; 6(6): 249-57.
[35]
Chen FH, Liu T, Xu L, Zhang L, Zhou XB. Association of serum vitamin D level and carotid atherosclerosis: A systematic review and meta-analysis. J Ultrasound Med 2018; 37(6): 1293-303.
[36]
McNally JS, Burton TM, Aldred BW, et al. Vitamin D and vulnerable carotid plaque. AJNR Am J Neuroradiol 2016; 37(11): 2092-9.
[37]
Belen E, Sahin I, Gungor B, et al. Assessment of 25-Hydroxyvitamin D levels in patients with resistant hypertension. Med Princ Pract 2016; 25(1): 25-30.
[38]
Poss J, Mahfoud F, Ukena C, et al. Association of vitamin D status and blood pressure response after renal denervation. Clin Res Cardiol 2014; 103(1): 41-7.
[39]
Siniscalchi A. Hyperhomocysteinemia in neurologic diseases. Recenti Prog Med 2004; 95(7-8): 371-5.
[40]
Siniscalchi A, Mancuso F, Gallelli L, Ferreri Ibbadu G, Biagio Mercuri N, De Sarro G. Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. Pharmacol Res 2005; 52(5): 367-75.
[41]
Al-Bayyari N, Al-Zeidaneen S, Hailat R, Hamadneh J. Vitamin D3 prevents cardiovascular diseases by lowering serum total homocysteine concentrations in overweight reproductive women: A randomized, placebo-controlled clinical trial. Nutr Res 2018; 59: 65-71.
[42]
Siniscalchi A, Sztajzel R, Bonci A, Malferrari G, De Sarro G, Gallelli L. Editorial: Cocaine and cerebral small vessel: Is it a negative factor for intravenous thrombolysis? Curr Vasc Pharmacol 2016; 14(3): 304-6.
[43]
Daumas A, Daubail B, Legris N, et al. Association between admission serum 25-Hydroxyvitamin D levels and functional outcome of thrombolyzed stroke patients. J Stroke Cerebrovasc Dis 2016; 25(4): 907-13.
[44]
Sayeed I, Turan N, Stein DG, Wali B. Vitamin D deficiency increases blood-brain barrier dysfunction after ischemic stroke in male rats. Exp Neurol 2019; 312: 63-71.
[45]
Andress DL. Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69(1): 33-43.
[46]
Verdoia M, Pergolini P, Rolla R, et al. Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Platelets 2016; 27(6): 576-82.
[47]
Lu BC, Shi XJ, Liang L, Dong N, Liu ZZ. Platelet surface CD62p and serum vitamin D levels are associated with clopidogrel resistance in chinese patients with ischemic stroke. J Stroke Cerebrovasc Dis 2019; 28(5): 1323-8.
[48]
Chung PW, Park KY, Kim JM, et al. 25-hydroxyvitamin D status is associated with chronic cerebral small vessel disease. Stroke 2015; 46(1): 248-51.
[49]
Zhang B, Wang Y, Zhong Y, Liao S, Lu Z. Serum 25-hydroxyvitamin D deficiency predicts poor outcome among acute ischemic stroke patients without hypertension. Neurochem Int 2018; 118: 91-5.
[50]
Manouchehri N, Vakil-Asadollahi M, Zandifar A, Rasmani F, Saadatnia M. Vitamin D status in small vessel and large vessel ischemic stroke patients: A case-control study. Adv Biomed Res 2017; 6: 146.
[51]
Larsson SC, Traylor M, Mishra A, Howson JMM, Michaelsson K, Markus HS. Serum 25-Hydroxyvitamin D concentrations and ischemic stroke and its subtypes. Stroke 2018; 49(10): 2508-11.
[52]
Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8(4): 174-9.
[53]
Xing N. ML LM, Bachman LA, McKean DJ, Kumar R, Griffin MD. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 2002; 297(3): 645-52.
[54]
O’Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272(4 Pt 2): H1751-8.
[55]
Gibson CC, Davis CT, Zhu W, et al. Dietary vitamin D and its metabolites non-genomically stabilize the endothelium. PLoS One 2015; 10(10)e0140370
[56]
Boskabadi H, Zakerihamidi M, Faramarzi R. The vitamin D level in umbilical cord blood in premature infants with or without intra-ventricular hemorrhage: A cross-sectional study. Int J Reprod Biomed (Yazd) 2018; 16(7): 429-34.
[57]
Zhou R, Wang M, Huang H, Li W, Hu Y, Wu T. Lower vitamin D status is associated with an increased risk of ischemic stroke: A systematic review and meta-analysis. Nutrients 2018; 10(3): 277.
[58]
Brondum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25-hydroxyvitamin D and symptomatic ischemic stroke: An original study and meta-analysis. Ann Neurol 2013; 73(1): 38-47.
[59]
Carbone LD, Rosenberg EW, Tolley EA, et al. 25-Hydroxyvitamin D, cholesterol, and ultraviolet irradiation. Metabolism 2008; 57(6): 741-8.
[60]
Sheerah HA, Eshak ES, Cui R, Imano H, Iso H, Tamakoshi A. Relationship between dietary vitamin D and deaths from stroke and coronary heart disease: The japan collaborative cohort study. Stroke 2018; 49(2): 454-7.
[61]
Manson JE, Cook NR, Lee IM, et al. Vitamin d supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2019; 380(1): 33-44.
[62]
Pilz S, Tomaschitz A, Drechsler C, Zittermann A, Dekker JM, Marz W. Vitamin D supplementation: A promising approach for the prevention and treatment of strokes. Curr Drug Targets 2011; 12(1): 88-96.
[63]
Ladeby R, Wirenfeldt M, Garcia-Ovejero D, et al. Microglial cell population dynamics in the injured adult central nervous system. Brain Res Brain Res Rev 2005; 48(2): 196-206.
[64]
Wei ZN, Kuang JG. Vitamin D deficiency in relation to the poor functional outcomes in nondiabetic patients with ischemic stroke. Biosci Rep 2018; 38(2)pii BSR20171509
[65]
Gupta A, Prabhakar S, Modi M, et al. Effect of Vitamin D and calcium supplementation on ischaemic stroke outcome: A randomised controlled open-label trial. Int J Clin Pract 2016; 70(9): 764-70.
[66]
Manson JE. Vitamin D and the heart: Why we need large-scale clinical trials. Cleve Clin J Med 2010; 77(12): 903-10.
[67]
LeBoff MS, Yue AY, Copeland T, Cook NR, Buring JE, Manson JE. VITAL-Bone Health: Rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials 2015; 41: 259-68.
[68]
Shaffer JA, Edmondson D, Wasson LT, et al. Vitamin D supplementation for depressive symptoms: A systematic review and meta-analysis of randomized controlled trials. Psychosom Med 2014; 76(3): 190-6.
[69]
Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115(7): 846-54.
[70]
Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ 2011; 342: d2040.
[71]
Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341: c3691.
[72]
Reid IR, Bristow SM, Bolland MJ. Cardiovascular complications of calcium supplements. J Cell Biochem 2015; 116(4): 494-501.
[73]
Mao PJ, Zhang C, Tang L, et al. Effect of calcium or vitamin D supplementation on vascular outcomes: A meta-analysis of randomized controlled trials. Int J Cardiol 2013; 169(2): 106-11.
[74]
Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M. Cardiovascular disease and vitamin D supplementation: Trial analysis, systematic review, and meta-analysis. Am J Clin Nutr 2014; 100(3): 746-55.
[75]
Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: A systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96(7): 1931-42.
[76]
Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: A trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014; 2(4): 307-20.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2019
Page: [178 - 183]
Pages: 6
DOI: 10.2174/1567202616666190412152948
Price: $58

Article Metrics

PDF: 20
HTML: 2